Another study detecting the circulating cell-free tumor-DNA (cft-DNA) of 29 PDAC patients showed that the survival of patients with detectable plasma KRAS mutations pre-treatment was significantly worse (16.8 months vs. not reached, p < 0.031) [27]. This evidence concerns the gene KRAS and neoplasm.